Drug intelligence / Profile preview

WGc-0801

Development stage: Preclinical
Lead developer: Chengdu Weisijin Biopharmaceutical Technology
Modality: mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics

Overview

WGc-0801 is a preclinical mRNA-based tumor vaccine being developed by WestGene for the treatment of solid tumors. As part of WestGene's tumor treatment vaccine platform, it is designed to elicit anti-tumor immunity by delivering mRNA encoding specific tumor-associated antigens. The vaccine aims to stimulate the patient's immune system to recognize and destroy malignant cells. It is currently in the preclinical stage of development and is intended to provide a novel therapeutic approach for various solid tumor types.

Beyond the preview

Go deeper on WGc-0801.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on WGc-0801.

Explore the full profile